Zolmitriptan Provides Consistent Migraine Relief when Used in the Long Term

References

• Stewart W. F., Lipton R. B., Celentano D. D., Reed M. L. Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors. JAMA 1992; 267: 64–91. Stewart W. F., Lipton R. B., Celentano D. D., Reed M. L. Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors. JAMA 1992; 267: 64–9
   PubMed Web of Science ®Google Scholar
• Stewart W. F., Shechter A., Rasmussen B. K. Migraine prevalence. Areview of population-based studies. Neurology 1994; 44: S17–523, (Suppl 4)2. Stewart W. F., Shechter A., Rasmussen B. K. Migraine prevalence. Areview of population-based studies. Neurology 1994; 44: S17–523, (Suppl 4)
   PubMed Web of Science ®Google Scholar
• Rasmussen B. I., Jensen R., Schroll M., Olesen J. Epidemiology of headache in a general population - a prevalence study. J. Clin. Epidemiol. 1991; 44: 1147–11573. Rasmussen B. I., Jensen R., Schroll M., Olesen J. Epidemiology of headache in a general population - a prevalence study. J. Clin. Epidemiol. 1991; 44: 1147–1157
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1998; 8: 1–96, (Suppl 7)4. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1998; 8: 1–96, (Suppl 7)
   Google Scholar
• Edmeads J., Findlay H., Tugwell P., Pryse-Phillips W., Nelson R. R., Murray T. J. Impact of migraine and tension-type headache on life-style, consulting behavior and medication use: a Canadian population survey. Can. J. Neurol. Sci. 1993; 20: 131–1375. Edmeads J., Findlay H., Tugwell P., Pryse-Phillips W., Nelson R. R., Murray T. J. Impact of migraine and tension-type headache on life-style, consulting behavior and medication use: a Canadian population survey. Can. J. Neurol. Sci. 1993; 20: 131–137
   PubMed Web of Science ®Google Scholar
• Lipton R. B., Stewart W. F., Celentano D. D., Reed M. Underdiagnosed migraine: a comparison of symptom-based and self-reported physician diagnosis. Arch. Intern. Med. 1992; 152: 1273–12786. Lipton R. B., Stewart W. F., Celentano D. D., Reed M. Underdiagnosed migraine: a comparison of symptom-based and self-reported physician diagnosis. Arch. Intern. Med. 1992; 152: 1273–1278
   PubMed Web of Science ®Google Scholar
• Rasmussen B. K., Jensen R., Olesen J. Impact of headache on sickness, absence and utilization of medical services: a Danish population-based study. J. Epidemiol. Cam. Health 1992; 46: 443–4467. Rasmussen B. K., Jensen R., Olesen J. Impact of headache on sickness, absence and utilization of medical services: a Danish population-based study. J. Epidemiol. Cam. Health 1992; 46: 443–446
   PubMed Web of Science ®Google Scholar
• Göbel H., Petersen-Braun M. Why patients with primary headaches do not consult a doctor. Headache Classifcation and Epidemiology, J. Olesen. Raven Press, New York 1994; 267–2728. Göbel H., Petersen-Braun M. Why patients with primary headaches do not consult a doctor. Headache Classifcation and Epidemiology, J. Olesen. Raven Press, New York 1994; 267–272
   Google Scholar
• Ferrari M. D. The economic burden of migraine to society. Pharmacoeconomics 1998; 13: 667–6769. Ferrari M. D. The economic burden of migraine to society. Pharmacoeconomics 1998; 13: 667–676
   PubMed Web of Science ®Google Scholar
• Clarke C. E., MacMillan L., Sondhi S., Wells N. E. Economic and social impact of migraine. Q. J. Med. 1996; 89: 77–8410. Clarke C. E., MacMillan L., Sondhi S., Wells N. E. Economic and social impact of migraine. Q. J. Med. 1996; 89: 77–84
   Google Scholar
• Solomon G. D., Price K. L. Burden of migraine: a review of its socioeconomic impact. Pharmacoeconomics 1997; 11: 1–10, (Suppl l)11. Solomon G. D., Price K. L. Burden of migraine: a review of its socioeconomic impact. Pharmacoeconomics 1997; 11: 1–10, (Suppl l)
   PubMed Web of Science ®Google Scholar
• Dahlof C., Dimenas E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995; 15: 31–3612. Dahlof C., Dimenas E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995; 15: 31–36
   PubMed Web of Science ®Google Scholar
• Goadsby P. J., Hoskin K. L. Inhibition of trigeminal neurones by intravenous administration of the serotonin (5HT)IB/ID agonist zolmitriptan (311C90): are brain stem sites therapeutic targets in migraine. Pain 1996; 67: 355–35913. Goadsby P. J., Hoskin K. L. Inhibition of trigeminal neurones by intravenous administration of the serotonin (5HT)IB/ID agonist zolmitriptan (311C90): are brain stem sites therapeutic targets in migraine. Pain 1996; 67: 355–359
   PubMed Web of Science ®Google Scholar
• Martin G. R. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HTIB/ID agonist for migraine. Cephalalgia 1997; 17: 4–14, (Suppl 18)14. Martin G. R. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HTIB/ID agonist for migraine. Cephalalgia 1997; 17: 4–14, (Suppl 18)
   PubMed Web of Science ®Google Scholar
• Rapoport A. M., Ramadan N. M., Adelman J. U., Mathew N. T., Elkind A. H., Kudrow D. B., Earl N. L., On behalf of the 017 Clinical Trial Study Group. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology. 1997; 49: 1210–121815. Rapoport A. M., Ramadan N. M., Adelman J. U., Mathew N. T., Elkind A. H., Kudrow D. B., Earl N. L., On behalf of the 017 Clinical Trial Study Group. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology. 1997; 49: 1210–1218
   PubMed Web of Science ®Google Scholar
• Solomon G. D., Cady R. K., Klapper J. A., Earl N. L., Saper J. R., Ramadan N. M., On behalf of the 042 Clinical Trial Study Group. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997; 49: 1219–122516. Solomon G. D., Cady R. K., Klapper J. A., Earl N. L., Saper J. R., Ramadan N. M., On behalf of the 042 Clinical Trial Study Group. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997; 49: 1219–1225
   PubMed Web of Science ®Google Scholar
• Dahlof C., Diener H. C., Goadsby P. J., Massiou H., Olesen J., Schoenen J., Wilkinson M., Sweet R. M., Klein K. B. Zolmitriptan a 5-HTIB/ID, receptor agonist for the acute oral treatment of migraine: a multicenter, dose-range finding study. Eur. J. Neurol. 1998; 5: 535–54417. Dahlof C., Diener H. C., Goadsby P. J., Massiou H., Olesen J., Schoenen J., Wilkinson M., Sweet R. M., Klein K. B. Zolmitriptan a 5-HTIB/ID, receptor agonist for the acute oral treatment of migraine: a multicenter, dose-range finding study. Eur. J. Neurol. 1998; 5: 535–544
   PubMed Web of Science ®Google Scholar
• The International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (‘Zomig’, 311C90) in the acute treatment of migraine. Headache 1998; 38: 173–18318. The International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (‘Zomig’, 311C90) in the acute treatment of migraine. Headache 1998; 38: 173–183
   PubMed Web of Science ®Google Scholar
• Tepper S., Donnan G. A., Dowson A. J., Bomhof M. A. M., Elkind A., Meloche J., Fletcher P. E., Millson D. S. A long-term study to maximize migraine relief with Zolmitriptan. Curr. Med. Res. Opin. 1999; 15(4)254–27119. Tepper S., Donnan G. A., Dowson A. J., Bomhof M. A. M., Elkind A., Meloche J., Fletcher P. E., Millson D. S. A long-term study to maximize migraine relief with Zolmitriptan. Curr. Med. Res. Opin. 1999; 15(4)254–271
   PubMed Web of Science ®Google Scholar
• Rapoport A. M., Adelman J. Consistent efficacy across and within patients treated with 2.5 or 5 mg zolmitriptan (Zomig™). Abstract and poster presentation at the 50th Meeting of the American Academy of Neurology; Minneapolis, 25 April-2 May 1998. Neurology 1998; 50: 265, (Suppl 4)20. Rapoport A. M., Adelman J. Consistent efficacy across and within patients treated with 2.5 or 5 mg zolmitriptan (ZomigTM). Abstract and poster presentation at the 50th Meeting of the American Academy of Neurology; Minneapolis, 25 April-2 May 1998. Neurology 1998; 50: 265, (Suppl 4)
   Google Scholar
• Patrick D. L., Hurst B. C. Consistency of meaningful migraine relief and quality of life in patients treated with Zomig™. Abstract and poster at the 40th Meeting of the American Association of the Study of Headache, San Francisco, 26–28 June, 1998. Headache 1998; 38: 39721. Patrick D. L., Hurst B. C. Consistency of meaningful migraine relief and quality of life in patients treated with ZomigTM. Abstract and poster at the 40th Meeting of the American Association of the Study of Headache, San Francisco, 26–28 June, 1998. Headache 1998; 38: 397
   Google Scholar